These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Lee CY; Huntley BK; McCormick DJ; Ichiki T; Sangaralingham SJ; Lisy O; Burnett JC Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):98-105. PubMed ID: 27340557 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and renal effect of CNAAC: An innovatively designed natriuretic peptide. Zhang S; Geng X; Zhao L; Li J; Tian F; Wang Y; Fan R; Feng N; Liu J; Cheng L; Pei J Eur J Pharmacol; 2015 Aug; 761():180-8. PubMed ID: 25979857 [TBL] [Abstract][Full Text] [Related]
5. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. Chen Y; Zheng Y; Iyer SR; Harders GE; Pan S; Chen HH; Ichiki T; Burnett JC; Sangaralingham SJ J Mol Cell Cardiol; 2019 May; 130():140-150. PubMed ID: 30954448 [TBL] [Abstract][Full Text] [Related]
7. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Chen HH; Cataliotti A; Schirger JA; Martin FL; Burnett JC Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1093-7. PubMed ID: 15627648 [TBL] [Abstract][Full Text] [Related]
8. Natriuretic peptide analogues with distinct vasodilatory or renal activity: integrated effects in health and experimental heart failure. Rademaker MT; Scott NJA; Koh CY; Kini RM; Richards AM Cardiovasc Res; 2021 Jan; 117(2):508-519. PubMed ID: 32167565 [TBL] [Abstract][Full Text] [Related]
9. Comparison of renal actions of urodilatin and atrial natriuretic peptide. Hildebrandt DA; Mizelle HL; Brands MW; Hall JE Am J Physiol; 1992 Mar; 262(3 Pt 2):R395-9. PubMed ID: 1313650 [TBL] [Abstract][Full Text] [Related]
10. Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation. Ma X; Iyer SR; Ma X; Reginauld SH; Chen Y; Pan S; Zheng Y; Moroni DG; Yu Y; Zhang L; Cannone V; Chen HH; Ferrario CM; Sangaralingham SJ; Burnett JC Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239899 [TBL] [Abstract][Full Text] [Related]
13. Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications. Chen Y; Burnett JC Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584705 [TBL] [Abstract][Full Text] [Related]
14. Renal effects of urodilatin in healthy subjects are independent of blockade of the cyclooxygenase and angiotensin II receptor. Carstens J; Pedersen EB Scand J Clin Lab Invest; 2008; 68(1):2-10. PubMed ID: 17852806 [TBL] [Abstract][Full Text] [Related]
15. The renal paracrine peptide system--possible urologic implications of urodilatin. Meyer M; Stief CG; Becker AJ; Truss MC; Taher A; Jonas U; Forssmann WG World J Urol; 1996; 14(6):375-9. PubMed ID: 8986039 [TBL] [Abstract][Full Text] [Related]
16. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502 [TBL] [Abstract][Full Text] [Related]
17. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. Dickey DM; Potter LR J Mol Cell Cardiol; 2011 Jul; 51(1):67-71. PubMed ID: 21459096 [TBL] [Abstract][Full Text] [Related]
18. Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. Carstens J; Greisen J; Jensen KT; Vilstrup H; Pedersen EB J Am Soc Nephrol; 1998 Aug; 9(8):1489-98. PubMed ID: 9697672 [TBL] [Abstract][Full Text] [Related]
19. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. McKie PM; Cataliotti A; Boerrigter G; Chen HH; Sangaralingham SJ; Martin FL; Ichiki T; Burnett JC Hypertension; 2010 Dec; 56(6):1152-9. PubMed ID: 20975033 [TBL] [Abstract][Full Text] [Related]
20. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Rademaker MT; Charles CJ; Kosoglou T; Protter AA; Espiner EA; Nicholls MG; Richards AM Am J Physiol; 1997 Nov; 273(5):H2372-9. PubMed ID: 9374774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]